SMARCB1 and neoplasm: Among the 46 specimens with available tumor necrosis rate data, we found significantly decreased SMARCB1 expression in poor responders to neoadjuvant chemotherapy (31/46) compared with those with a favorable response (14/46) (1.8 ± 1.5 versus 3.4 ± 1.5, P=0.003) (Figure 3D).